![Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: A new brain tumor entity? | Request PDF Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: A new brain tumor entity? | Request PDF](https://i1.rgstatic.net/ii/profile.image/989047140929539-1612818622032_Q64/Despoina-Ntenekou.jpg)
Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: A new brain tumor entity? | Request PDF
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/1028072774066176-1622123058164_Q64/Ankur-Patel-38.jpg)
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
![Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF](https://i1.rgstatic.net/ii/profile.image/1075921004044288-1633530965884_Q64/Ioannis-Ziogas.jpg)
Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://c5.rgstatic.net/m/437738464651637/images/template/default/profile/profile_default_l.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
![Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF](https://i1.rgstatic.net/ii/profile.image/970534665863168-1608404904294_Q64/Raquel-Sopena-Sutil.jpg)
Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://i1.rgstatic.net/ii/profile.image/1011183721144321-1618096394897_Q128/Jing-Zhao-99.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/1012822234374150-1618487046512_Q64/V-Batumalai.jpg)
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
![Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery](https://www.researchgate.net/profile/Emil-Martin/publication/51640136/figure/fig7/AS:668829864689676@1536472874805/Inhibition-of-glioma-cell-proliferation-by-pharmacological-restoration-of-cGMP-Treatment_Q320.jpg)
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/966473229008899-1607436582351_Q64/Ioannis-Georgakopoulos-2.jpg)
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
![Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery](https://www.researchgate.net/publication/330298395/figure/fig3/AS:713721433309186@1547175858465/Patient-plans-with-high-maximum-doses-experience-a-substantial-reduction-in-the-maximum_Q320.jpg)
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
![Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery](https://www.researchgate.net/profile/Ioannis-Nezis/publication/44676885/figure/fig3/AS:271111430602769@1441649410423/CIN85Dex2-knockout-mice-display-metabolic-and-behavioural-phenotypes-A-CIN85Dex2_Q320.jpg)
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://www.researchgate.net/publication/337962528/figure/fig4/AS:836929050394624@1576550843148/Graphical-representation-of-overall-survival-OS-for-a-trials-of-NCCN-recommended_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
![Breast Cancer in HIV-Positive Women: A Report of Four Cases and Review of the Literature | Request PDF Breast Cancer in HIV-Positive Women: A Report of Four Cases and Review of the Literature | Request PDF](https://i1.rgstatic.net/ii/profile.image/1000252484096006-1615490184354_Q64/Zahra-Shafaee.jpg)
Breast Cancer in HIV-Positive Women: A Report of Four Cases and Review of the Literature | Request PDF
![Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery](https://www.researchgate.net/publication/330298395/figure/fig1/AS:713721433313283@1547175858387/Automatically-created-treatment-fields-Beams-eye-view-of-the-A-anteroposterior-AP_Q320.jpg)
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
![Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF](https://i1.rgstatic.net/ii/profile.image/962133550440448-1606401922057_Q64/Joseph-Kim-34.jpg)
Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF
![Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF](https://i1.rgstatic.net/ii/profile.image/958989760204803-1605652384490_Q64/Jean-Philippe-Pignol-2.jpg)
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://www.researchgate.net/publication/337962528/figure/fig2/AS:836929050390529@1576550843107/Historical-objective-response-rate-ORR-with-chemotherapy-in-2L-mTNBC-Meta-analysis-of_Q320.jpg)
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
![Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology](https://i1.rgstatic.net/ii/profile.image/283535337377793-1444611500964_Q128/Syn-Yeo.jpg)